Skip to main content

Table 1 patient and treatment characteristics

From: Stereotactic body radiation therapy (SBRT) in patients with hepatocellular carcinoma and oligometastatic liver disease

  entire cohort HCC MD
number of patients 55 27 28
number of lesions 70 36 34
single/multiple lesions 40/15 18/9 22/6
gender (male/female) 35/20 19/8 16/12
age (median/range in years) 64/31–83 63/46–83 67/31–80
KPS (median/range in %) 90/60–100 90/60–100 95/70–100
histology (CRC/LC/BC/S/O) 10/4/4/2/9
Child-Pugh stage (A/B/C) 21/5/1
fiducials (n/%) 42/76 18/67 24/86
abdominal compression (n/%) 26/47 14/52 12/43
GTV per patient (median/range in ccm) 14.6/0.4–204 15.5/1.2–204 13.25/0.4–98.2
GTV per lesion (median/range in ccm) 6.6/0.2–204 7.5/0.9–204 6.2/0.2–98.2
PTV per patient (median/range in ccm) 75.5/17.7–511.6 92.7/17.7–511.6 61.1/19.3–314
PTV per lesion (median/range in ccm) 59/15–512 61/15–512 51/15–314
dose concept (3 × 12.5/5 × 8/other) 28/11/16 16/6/5 12/5/9
BED max (median/range) 168.1/60.3–190 168.2/60.3–168.2 118/80.4–190
actual treatment (SBRT/TACE+SBRT) 12/15
  1. HCC: hepatocellular carcinoma, MD: metastatic disease, KPS: Karnofsky performance score, CRC: colorectal cancer, LC: lung cancer, BC: breast cancer, S: sarcoma, o: other, GTV: gross tumor volume [cubic centimeters], PTV: planning target volume [cubic centimeters], BED: biologically equivalent dose, SBRT: stereotactic body radiotherapy, TACE: transarterial chemoembolization, all doses in [Gy]